Markets
markets

Moderna rises after positive flu vaccine trial results, paving way for combo shot

Moderna rose more than 5% in premarket trading after announcing positive results for its experimental flu vaccine, paving the way for a combination COVID-19 immunization.

The company’s mRNA-based flu shot was 27% more effective than the shots already on the market among adults 50 years and older, the company said in a statement Monday. Moderna disclosed in May that it tried to submit a combination Covid and flu shot for FDA approval, but regulators asked for more efficacy data on its stand-alone flu shot.

The news is a rare bright spot for Moderna amid a tumultuous year. The companys main revenue source is COVID-19 shots, but sales are declining. Under the Trump administration its been met with a more hostile FDA, which has narrowed its recommendation for who should get Covid shots and canceled a contract for Moderna to develop a bird flu vaccine.

More Markets

See all Markets
markets

SpaceX gets a wave of bullish ratings from Wall Street analysts

SpaceX received more than a dozen positive analyst calls on Tuesday — including from major Wall Street banks — as they initiate coverage on Elon Musk’s space and AI company.

SpaceX went public on June 12 at a $2.2 trillion valuation, the largest debut in history. While the company hasn’t yet posted a profit, it seems to have convinced Wall Street that it will get there and grow its valuation on the way.

Of the at least 17 analysts that gave a rating on Tuesday, all but one gave it a “buy” or “outperform” rating. MoffettNathanson was "neutral."

The ratings come as SpaceX joined the Nasdaq 100 index, a benchmark tech-heavy basket of companies that underpins millions of portfolios. The inclusion adds built-in demand for the stock from index funds and ETFs.

Still, SpaceX fell more than 5% on Tuesday amid a broader sell-off, and is currently effectively flat from its opening price of $150 a share.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.